Disclosures for "Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS"
-
Ms. Fleming has received personal compensation for serving as an employee of ProJenX. Ms. Fleming has received personal compensation for serving as an employee of Project ALS. Ms. Fleming has stock in ProJenX.
-
Miss Salmon has received personal compensation for serving as an employee of QurAlis Corporation. Miss Salmon has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for ProJenX. Miss Salmon has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with ALS Canada.
-
April Ruby has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for ProJenX, Inc.
-
Hilde Williams has received personal compensation for serving as an employee of Vima Therapeutics, Inc.. The institution of Hilde Williams has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ProJenX Inc.. Hilde Williams has stock in PharmaStory Corp.. Hilde Williams has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Danielsson-Sanden has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ProJenX.